Biomarker and therapeutic applications of a novel microRNA in early-stage knee

osteoarthritis

Madhu Baghel PhD[1,2], Thomas G. Wilson BS[1,2], Trevor Banka MD[2], Jason Davis MD[3,4], Vasilios

Moutzouros MD[2], Shabana Amanda Ali PhD[1,2,5,6*]

Affiliations: 1. Bone and Joint Center, Henry Ford Health + Michigan State University Health

Sciences, Detroit, MI, USA; 2. Department of Orthopedic Surgery, Henry Ford Health, Detroit, MI,

USA; 3. Michigan Orthopaedic Surgeons, West Bloomfield, MI, USA; 4. Department of

Orthopaedic Surgery, Corewell Health William Beaumont University Hospital, Royal Oak, MI,

USA; 5. Department of Physiology, Michigan State University, East Lansing, MI, USA; 6. Center

for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA

*Corresponding author:

Shabana Amanda Ali, PhD

Bone and Joint Center, Henry Ford Health, 6135 Woodward Avenue, Detroit MI 48202, USA

Email: sali14@hfhs.org

Abstract

Osteoarthritis is a debilitating joint disease with no known cure, underscoring the need for early detection and intervention. Given their potential disease-specificity, novel microRNAs are promising biomarkers and therapeutic targets. Novel microRNAs are identified from sequencing data using bioinformatics analyses. Here we aimed to characterize a novel microRNA (novel_miRNA_2; UCCCUGUUCGGGCGCCACU) in knee osteoarthritis. We show circulating novel_miRNA_2 accurately distinguishes early-stage knee osteoarthritis from both non-osteoarthritis and late-stage knee osteoarthritis. In knee osteoarthritis subchondral bone, novel_miRNA_2 functions as a canonical microRNA, downregulating target genes such as *RUNX2*. In male mice, novel_miRNA_2 mimic attenuates knee osteoarthritis when delivery begins in early stages, but not late stages. The decline in novel_miRNA_2 in late-stage knee osteoarthritis may be governed by Hedgehog signaling, which is known to upregulate genes such as *RUNX2* and exacerbate osteoarthritis. Our findings suggest endogenous novel_miRNA_2 can be used to detect early-stage knee osteoarthritis when exogenous delivery can mitigate disease.

Keywords

Arthritis, Early Diagnosis, Epigenetics, Targeted therapy

Introduction

Osteoarthritis (OA) is a debilitating joint disease currently impacting 7.6% of the global population[1]. Most commonly affecting the knee[1], OA is characterized by phasic symptoms and progressive joint damage, including articular cartilage degradation, synovial inflammation, and subchondral bone remodeling[2]. There is no known cure for OA, and the molecular mechanisms that drive OA pathogenesis are incompletely understood, particularly in early-stage disease when prevention is still possible[3]. This points to a need for reliable biomarkers that can detect early-stage OA and for effective therapeutics that can mitigate disease progression[4].

MicroRNAs are small non-coding RNAs with the potential to serve as both mechanistic biomarkers and therapeutic targets in OA[5]. Functioning to repress gene expression via direct binding to their target mRNAs[6], microRNAs regulate key biological processes in joint tissues[7]. As biomarkers, circulating microRNAs are highly stable and can be linked to specific disease contexts[8]. As therapeutics, microRNAs can be modulated using small molecules to either enhance or inhibit their activity *in vivo* to mitigate disease processes[5,9]. Their dual function as mechanistic biomarkers and therapeutic targets can link diagnosis to treatment, making microRNAs strong candidates for precision medicine in OA.

Most studies to date have focused on established microRNAs that are cataloged in databases[10] and characterized across different biological contexts[11]. In contrast, novel microRNAs are sequences that are newly discovered through bioinformatics analyses of microRNA-sequencing data[12]. Novel microRNAs align to the human reference genome, have a predicted hairpin secondary structure typical of microRNA precursors, and lack homology with established microRNAs in humans and other species[13]. With the potential to be completely unique to the biological context in which they are discovered, novel microRNAs are ideal for first-in-class

microRNA biomarkers and therapeutics for OA. Despite their promise, the biological relevance

and clinical utility of novel microRNAs in OA remains largely unknown.

In the first study to explore circulating novel microRNAs in OA, four candidates (novel_miRNA_1,

novel_miRNA_2, novel_miRNA_3, and novel_miRNA_4) were found to be more prevalent in

plasma from individuals with early- versus late-stage radiographic knee OA[14]. Here, we evaluate

the biomarker potential of these four candidates in an independent patient cohort and prioritize

novel_miRNA_2. Using both primary human knee OA tissues and a surgical mouse model of

knee OA, we define expression profiles and therapeutic effects of novel_miRNA_2. Together, our

findings suggest that novel_miRNA_2 is a promising biomarker for early-stage knee OA that

functions as a canonical microRNA to prevent disease by repressing aberrant bone-related

processes.

<u>Results</u>

Circulating novel_miRNA_2 distinguishes early-stage knee OA

Four novel microRNAs were previously reported in the plasma of individuals with early- versus

late-stage radiographic knee OA[14] (**Figure 1A**). To validate these findings, we leveraged the

Henry Ford Health (HFH) OA Cohort, a repository of human biofluids, tissues, and

clinicodemographic data from individuals with symptomatic knee OA undergoing arthroscopy or

arthroplasty. Participants were stratified by radiographic severity using the Kellgren-Lawrence

(KL) grading system, with KL grade 0 or 1 defined as early-stage knee OA[15] and KL grade 3 or 4

as late-stage knee OA, consistent with previous definitions[14]. Non-OA plasma samples were

obtained from the "Control Cohort" of the Osteoarthritis Initiative (OAI)[16] and included individuals

with no symptomatic or radiographic evidence of knee OA.

Performing real-time PCR (RT-qPCR) using custom-designed TaqMan assays, no significant differences were observed for novel_miRNA_1, novel_miRNA_3, or novel_miRNA_4 (**Supplemental Figure 1**), but novel_miRNA_2 was significantly elevated in early-stage knee OA plasma compared to non-OA controls and late-stage knee OA (**Figure 1B**). When including KL grade 2 samples, plasma levels of novel_miRNA_2 showed a significant inverse correlation with KL grade (**Figure 1C**). Based on these findings, we evaluated the potential of novel_miRNA_2 to distinguish early-stage knee OA using area under the receiver operating characteristic curve analysis (AUC). Novel_miRNA_2 showed excellent accuracy in discriminating early-stage knee OA from non-OA and good accuracy from late-stage knee OA (**Figure 1D**), as well as good accuracy in distinguishing late-stage knee OA from non-OA (**Supplemental Figure 2**). Using multivariable linear regression, we confirmed there were no associations between novel_miRNA_2 plasma levels and age, sex, or body mass index (BMI), but significant associations with early-stage knee OA (**Figure 1E**). Collectively, these findings prioritize novel_miRNA_2 as a promising circulating biomarker for early-stage knee OA.

Novel_miRNA_2 functions as a canonical microRNA

Since novel_miRNA_2 was predicted to be a microRNA using only bioinformatics analyses[14], we aimed to experimentally verify its authenticity based on known properties of canonical microRNAs[6]. MicroRNA biogenesis begins with transcription of a primary ("pri-") transcript from a host gene, which folds into a hairpin structure[6]. This precursor undergoes enzymatic cleavages to generate mature microRNAs that are loaded into Argonaute 2 (AGO2)-containing RNA-induced silencing complexes (RISCs) to mediate repression of target genes[6] (**Figure 2A**). Prior to experimentation, we aligned the predicted novel_miRNA_2 precursor to the human reference genome (GRCh38) and identified its host gene as Zinc Finger Protein 773 (*ZNF773*), with novel_miRNA_2 located on the reverse strand (**Figure 2B**). We also identified the mature

novel_miRNA_2 sequence on the 5' arm of the precursor molecule, which designates it as a "-

5p" microRNA by standard conventions[17] (**Figure 2B**).

We leveraged the steps of microRNA biogenesis to identify the knee OA tissues that express

novel_miRNA_2. Specifically, we quantified *ZNF773*, pri-novel_miRNA_2, and mature

novel_miRNA_2 in subchondral bone, infrapatellar fat pad ("fat pad"), articular cartilage, and

synovium using RT-qPCR. In early- versus late-stage knee OA tissues, *ZNF773* was significantly

higher in subchondral bone, fat pad, and synovium (**Figure 2C**), pri-novel_miRNA_2 was higher

in subchondral bone and fat pad (**Figure 2D**), and mature novel_miRNA_2 was higher in

subchondral bone, fat pad, synovium, and articular cartilage (**Figure 2E**). Since the mature form

is derived from the primary transcript, we performed correlation analyses between mature

novel_miRNA_2 and pri-novel_miRNA_2 levels and found significant positive associations in

subchondral bone (n = 14, R = 0.69, p = 0.01) and fat pad (n = 14, R = 0.67, p = 0.01). To assess

incorporation of novel_miRNA_2 into RISCs, we performed an AGO2-RNA immunoprecipitation

assay in human knee OA subchondral bone (**Figure 2F**). We found significant enrichment of

novel_miRNA_2 in AGO2-bound fractions compared with IgG fractions, while there was no

enrichment of negative control U6 small nuclear RNA (**Figure 2G**). Taken together, these results

show that novel_miRNA_2 is elevated in early- versus late-stage knee OA tissues and follows

canonical microRNA biogenesis most consistently in subchondral bone.

Novel_miRNA_2 inhibits target genes in knee OA subchondral bone

To elucidate molecular mechanisms of novel_miRNA_2 in knee OA, we sought to identify its direct

target genes. MicroRNAs inhibit gene expression through complementary seed-sequence

binding, most often within the 3' untranslated region (UTR) of a target mRNA[6]. Using an *in silico*

approach[18], we first identified 2,951 human genes that contained at least one putative 7mer or

8mer novel_miRNA_2 seed-sequence binding site in their 3' UTR (**Figure 3A**). Second, we

evaluated binding site stability by calculating the Gibbs free energy (ΔG) for the 70-nucleotide

flanking regions of each binding site, comparing them with 3' UTR-wide averages. Sites with

greater than average flanking ΔG were retained, indicative of less stable mRNA secondary

structures and higher accessibility for RISC binding[19], resulting in 1,463 genes (**Figure 3A**). Third,

to focus on OA, we cross-referenced this list with bone-related datasets curated in OsteoDIP[20],

leaving 87 genes (**Figure 3A**). Finally, we performed pathway analysis[21] on this subset and found

enrichment of curated 'Diseases and Functions' and 'Canonical Pathways' that relate to OA

(**Supplemental Figure 3**), resulting in a final shortlist of 13 candidate target genes (**Figure 3B**).

To validate these predicted targets, we transfected human knee OA subchondral bone explants

with a custom-designed novel_miRNA_2 mimic to enhance its levels and then assessed

expression of the 13 genes (**Figure 3C**). Nine genes (*ASPN*, *RUNX2*, *ATRNL1*, *ADRA2A*,

SLC2A4, *ITGA11*, *IL11*, *ALPL*, and *MMP25*) were significantly downregulated with

novel_miRNA_2 mimic treatment versus negative control treatment, and four genes (*APOD*,

PARD6G, *ADIPOQ,* and *LEP*) were not significantly different (**Figure 3C**). These results are

consistent with the expected inhibitory effect of microRNAs on their direct target genes[6]. To

assess functional effects of novel_miRNA_2 in subchondral bone, we explored bone

mineralization, a process required for the osteophyte formation and subchondral sclerosis

observed in OA[22]. In murine pre-osteoblast cells transfected with novel_miRNA_2 mimic**,** there

was a significant reduction in mineral deposition compared to negative control (**Figure 3D, E**).

Together, these results suggest that novel_miRNA_2 functions to regulate target genes and bone-

related processes such as mineralization in knee OA subchondral bone.

Novel_miRNA_2 has a protective effect in early-stage knee OA

To assess the effect of novel_miRNA_2 on knee OA *in vivo*, we leveraged the partial medial

meniscectomy (PMX) mouse model[23]. Since species specificity was a criterion used to discover

novel_miRNA_2, it is predicted to occur in humans but not mice[13,14]. Consistent with this, we found

no matching sites upon aligning either the precursor or mature novel_miRNA_2 sequences to the

mouse reference genome (GRCm39). We were therefore able to precisely control

novel_miRNA_2 levels in mice using mimic treatments. Based on our data showing

novel_miRNA_2 is elevated in circulation during early-stage knee OA (**Figure 1B**), and previous

literature characterizing OA pathology in PMX mice over time[24], we compared intravenous

treatment beginning at two different timepoints (**Figure 4A**). Early treatment began one week

post-operatively, when cartilage degradation, osteophyte formation, and synovitis are all

underway, while late treatment began four weeks post-operatively, when these processes are

more established[24] (**Figure 4A**). To first confirm that the novel_miRNA_2 mimic was reaching

knee tissues following intravenous delivery, we performed *in situ* hybridization and observed a

positive signal in the subchondral bone of mimic-treated mice one week post-surgery compared

to negative control treatment (**Figure 4B**). Notably, signal intensity was greater in PMX knees

compared to sham knees (**Figure 4B**), suggesting that circulating novel_miRNA_2 accumulates

in mouse tissues during knee OA, as observed in human tissues (**Figure 2E**).

To assess knee OA severity, we evaluated cartilage degradation, osteophyte burden, and

synovitis as well-characterized features in the PMX model[24]. Compared to negative control

treatment, we found novel_miRNA_2 mimic reduced cartilage degradation (**Figure 4C, D**) and

osteophyte burden (**Figure 4E, F**) in PMX knees, but only when treatments began at earlier stages

and not later stages. No significant effect on synovitis was observed with either treatment strategy

(**Supplemental Figure 4**). These findings suggest novel_miRNA_2 likely functions to mitigate

tissue-specific disease processes in early stages of OA, but cannot reverse those processes once

established in later stages.

Hedgehog signaling may regulate novel_miRNA_2 levels in knee OA

Given the disease stage-dependent biomarker (**Figure 1**) and therapeutic (**Figure 4**) patterns

exhibited by novel_miRNA_2, we sought to identify upstream factors governing its levels in early-

versus late-stage knee OA. Taking an *in silico* approach to identifying transcription factor binding

sites within the promoter region of the *ZNF773* host gene, we found three GLI consensus binding

motifs located within 2.5 kb of novel_miRNA_2 (**Figure 5A**). GLI transcription factors are the

primary effectors of the Hedgehog (Hh) signaling pathway, which is known to exacerbate knee

OA[25]. Since Hh signaling upregulates Runt Related Transcription Factor 2 (*RUNX2)*[25], a regulator

of bone formation[26] and a predicted target gene of novel_miRNA_2 (**Figure 3B, C**), we

hypothesized that Hh signaling governs novel_miRNA_2 levels in knee OA subchondral bone.

To investigate Hh signaling in early- versus late-stage human knee OA subchondral bone, we

measured the Hh target genes GLI Family Zinc Finger 1 (*GLI1*), Patched 1 (*PTCH1*), and

Hedgehog Interacting Protein (*HHIP*) as markers of pathway activity[25,27]. All three targets were

lower in early- versus late-stage knee OA subchondral bone, as were levels of *RUNX2* (**Figure**

5B), consistent with the positive relationship previously reported between Hh signaling and

RUNX2 levels[25]. Together with the higher levels of *ZNF773*, pri-novel_miRNA_2, and mature

novel_miRNA_2 we observed in early-stage knee OA subchondral bone (**Figure 2C-E**), these

findings point to an inverse relationship between Hh signaling and novel_miRNA_2.

To assess the extent to which Hh signaling regulates novel_miRNA_2 levels, we treated human

knee OA subchondral bone explants with the Hh agonist purmorphamine[28] or vehicle control

(**Figure 5C**). Hh pathway activation by purmorphamine was confirmed by an increase in *GLI1*,

PTCH1, and *HHIP* compared to vehicle control (**Figure 5D**). Concurrently, we observed

significant reductions in *ZNF773*, pri-novel_miRNA_2, and mature novel_miRNA_2, along with

increased expression of *RUNX2* (**Figure 5D**). These findings suggest that Hh signaling can

reduce novel_miRNA_2 and remove the inhibitory effect novel_miRNA_2 has on target genes

such as *RUNX2.* Consistent with this, when novel_miRNA_2 levels were restored via mimic

treatment (**Figure 5C**), *RUNX2* expression decreased, even in the presence of Hh agonist

(**Figure 5E**). Taken together, these findings suggest that Hh signaling may govern the decline in

novel_miRNA_2 levels from early- to late-stage knee OA, and when restored, novel_miRNA_2

can mitigate the effect of Hh signaling on *RUNX2* in knee OA subchondral bone (**Figure 6**).

<u>Discussion</u>

Here we characterize a novel microRNA with the potential to be unique to OA. The

novel_miRNA_2 sequence has been reported by two studies profiling circulating novel

microRNAs in OA[14,29], but has not been reported in other studies profiling novel microRNAs in

non-OA human biospecimens[12,30,31]. We show circulating novel_miRNA_2 can distinguish early-

stage knee OA from both non-OA controls and late-stage knee OA, suggesting utility as a

minimally invasive biomarker. In human knee OA subchondral bone, novel_miRNA_2 functions

as a canonical microRNA that is transcribed from the *ZNF773* host gene, processed from primary

transcript into mature form, and incorporated into AGO2-containing RISCs to inhibit putative direct

target genes such as *RUNX2*. In a preclinical model, novel_miRNA_2 mimic reduces osteophyte

burden and cartilage degradation when administered beginning in early, but not later stages of

knee OA, suggesting it has a preventative effect but not a restorative effect. The decline in

novel_miRNA_2 levels from early- to late-stage disease may be regulated in part by Hh signaling,

which becomes activated in later stages of knee OA and upregulates *RUNX2*, potentially by

inhibiting novel_miRNA_2. To our knowledge, this study is the first comprehensive

characterization of a circulating novel microRNA in OA.

Reliable biomarkers for early-stage knee OA can transform clinical care by identifying patients for

first-line interventions before irreversible joint damage has occurred. While serum biomarkers

such as cartilage oligomeric matrix protein[32] and matrix metallopeptidase 3[33] have been explored

in early-stage knee OA, these are not yet in clinical use and are subject to challenges associated

with protein biomarkers[34]. MicroRNA biomarkers have been explored in knee OA[35] and other

musculoskeletal diseases[36], but novel microRNAs offer unique advantages. Novel microRNAs

may confer greater specificity and sensitivity as biomarkers since they are considered to be less

evolutionarily conserved than established microRNAs, often displaying species-specific or

lineage-restricted expression patterns[12,31]. Here, we show circulating novel_miRNA_2 in early-

stage knee OA can distinguish both the presence of OA and stage of OA[37], suggesting it has

potential as a diagnostic biomarker. Though not explored in the current study, novel_miRNA_2

may also have potential as a prognostic biomarker[37], where patients with higher levels of

novel_miRNA_2 or longer exposure to novel_miRNA_2 experience slower rates of OA

progression. This biomarker potential, together with its protective effects on knee OA, position

novel_miRNA_2 as a promising candidate for precision medicine linking patient stratification to

targeted interventions, where endogenous novel_miRNA_2 can be used to detect early-stage

knee OA and exogenous supplementation can mitigate disease progression.

Our data show novel_miRNA_2 functions as a canonical microRNA in human knee OA

subchondral bone and reduces osteophyte burden in mice with knee OA, suggesting it regulates

bone-related processes. Structural changes in bone are commonly observed in OA[38] and can

have negative effects on surrounding tissues[39], including cartilage[40]. As such, preventing

abnormal bone-related processes in early-stage knee OA via novel_miRNA_2 offers a viable

therapeutic strategy. It remains unknown if novel_miRNA_2 reduces cartilage damage indirectly,

via changes in bone, or more directly, via regulation of cartilage-related target genes, but available

evidence suggests the former. In early-stage knee OA cartilage, the trends towards elevated

novel_miRNA_2 biogenesis we observed were not significant. Consistent with this, a study

profiling novel microRNAs in human osteoarthritic chondrocytes did not report the

novel_miRNA_2 sequence[41], though this may be due to the study design. Meanwhile in early-

stage knee OA fat pad, we show novel_miRNA_2 biogenesis is elevated. The fat-related target

genes we predicted did not show significant differences with novel_miRNA_2 modulation in

subchondral bone, but they may be regulated by novel_miRNA_2 in fat pad, as microRNAs are

known to have tissue-specific effects[42]. In support of tissue specificity, novel_miRNA_2 had no

effect on synovitis in mice with knee OA, and therefore is unlikely to act on synovium. In this study

we prioritized bone-related genes previously implicated in OA, yet we predicted nearly 3,000

direct targets of novel_miRNA_2. Thus, there is a need to elucidate the network of

novel_miRNA_2 target genes within and across joint tissues to understand its role in OA, including

in regulating entirely new disease mechanisms.

The biomarker and therapeutic potential exhibited by novel_miRNA_2 specifically in early-stage

knee OA led us to investigate factors governing this stage-dependent activity. Given our focus on

subchondral bone and the presence of GLI consensus binding motifs upstream of

novel_miRNA_2, we explored Hh signaling, which is known to upregulate *RUNX2* and exacerbate

OA in late stages[25]. We hypothesize the lack of Hh signal in early-stage knee OA allows

novel_miRNA_2 biogenesis to proceed and inhibit *RUNX2*, while the presence of Hh signal in

late-stage knee OA reduces novel_miRNA_2 via GLI repressor isoforms[43], leaving target genes

such as *RUNX2* unchecked and promoting aberrant bone-related processes. Under this

hypothesis, sustaining novel_miRNA_2 levels from early- to late-stage knee OA is a strategy to

mitigate the effects of Hh signaling. This approach may be preferred over inhibition of Hh

signaling, which can have off-target effects[44]. Further research is needed to define parameters

such as the optimal treatment window for use of novel_miRNA_2 as a therapeutic in knee OA.

To note limitations of this study, validation in larger, independent cohorts is required to assess

the generalizability and clinical utility of novel_miRNA_2 as a diagnostic or prognostic biomarker.

Additionally, while *in silico* analyses were used to predict direct target genes of novel_miRNA_2,

transcriptional regulation must be verified through reporter construct assays, and indirect target

genes must be considered. Finally, we do not perform intra-articular delivery of novel_miRNA_2

mimic to target the local joint environment in mice. However, we show intravenous delivery of

mimic leads to localization in mouse knee OA tissues, which can be considered a less invasive

treatment approach that is amenable to future clinical translation[45].

In conclusion, this study demonstrates the potential of novel microRNAs to serve as biomarkers

and therapeutic targets in complex diseases. We show novel_miRNA_2 is associated with early-

stage knee OA, functioning as a canonical microRNA in subchondral bone to mitigate bone-

related processes. With further development, this microRNA could support precision medicine

approaches in OA care, being used as a biomarker to identify early-stage knee OA patients and

a therapeutic to prevent disease progression by targeting tissue-specific mechanisms.

Methods

Ethical approval and study cohort

Early- and late-stage knee OA biospecimens were obtained from the HFH OA Cohort. Assessed

by an orthopedic surgeon, the early-stage knee OA group comprised symptomatic individuals

undergoing knee arthroscopy with KL grade 0 or 1[15,29], and the late-stage knee OA group

comprised symptomatic individuals undergoing total knee arthroplasty with KL grade 3 or 4[14].

Non-OA plasma samples were obtained from the Osteoarthritis Initiative (OAI) "Control Cohort",

comprising individuals without knee symptoms, radiographic knee OA, or risk factors for OA.

Further details about the OAI are available at: https://nda.nih.gov/oai[16]. Clinicodemographic

variables, including age, self-reported sex, BMI, race, and comorbidities were collected and de-

identified for all participants (**Supplemental Table 1**). Ethical approval was obtained from the

HFH Institutional Review Board (IRB #13995) for the HFH OA Cohort and via the University of

California, San Francisco (FWA approval #00000068; IRB approval #10-00532) for the OAI. All

methods were performed following the Declaration of Helsinki guidelines[46].

Briefly, whole blood samples were centrifuged at 3200 x g for 10 minutes at 4°C to obtain plasma.

Early- and late-stage knee OA tissues were collected and processed using our published

protocols[47] and included subchondral bone, infrapatellar fat pad, articular cartilage, and synovium.

Tissues were collected intraoperatively and dissected under sterile conditions within four hours of

surgery. Biospecimens were either used immediately after processing or flash frozen in liquid

nitrogen and stored at -80°C until use.

Real-time quantitative polymerase chain reaction (RT-qPCR)

For plasma, RNA was isolated using the miRNeasy Serum/Plasma Advanced Kit (QIAGEN)

according to the manufacturer's instructions. For tissue explants, RNA was extracted following

our published protocols[47]. Briefly, this included tissue homogenization in TRIzol reagent

(Thermofisher Scientific) followed by two rounds of chloroform extraction, then precipitation with

100% isopropanol. Pellets were washed with ice-cold 75% ethanol, air-dried, and eluted in

nuclease-free water. RNA quality and concentration were determined using a NanoDrop 2000

spectrophotometer (Thermofisher Scientific).

For microRNA quantification, reverse transcription was performed using the TaqMan microRNA

Reverse Transcription Kit (Applied Biosystems) with custom TaqMan Small RNA assays (Applied

Biosystems). For gene expression analyses, cDNA was synthesized using the High-Capacity

cDNA Reverse Transcription Kit (Applied Biosystems). RT-qPCR was performed using a

QuantStudio 7 Pro system (Applied Biosystems) with TaqMan Small RNA/Gene Expression

Assays (Applied Biosystems) or SYBR Green-based DNA oligonucleotides (Sigma-Aldrich). A list

of probes and primers is provided in **Supplemental Table 2**. MiR-24-3p and *GAPDH* were used

as internal reference controls for microRNA and gene analyses, respectively, as done previously[8].

Relative expression levels were calculated using the delta-delta-Ct method[48].

Novel_miRNA_2 mimic transfection

A custom miRIDIAN microRNA mimic (Dharmacon) corresponding to the novel_miRNA_2

sequence (UCCCUGUUCGGGCGCCACU) was designed for use both *in vitro* and *in vivo*. This

synthetic double-stranded RNA oligonucleotide comprised the mature novel_miRNA_2 sequence

and its complement, with chemical enhancements to preferentially select the mature

novel_miRNA_2 sequence for loading into RISCs. Mimic specificity was confirmed by RT-qPCR

standard curve analysis. Primary human subchondral bone explants (~100 mg/well) were

transfected in 24-well plates with 100 nM novel_miRNA_2 mimic or miRIDIAN Human Negative

Control Mimic ("negative control"). Transfection was performed using DharmaFECT-1

(Dharmacon) transfection reagent in 500 μL/well serum-free Dulbecco's Modified Eagle's Medium

(DMEM) supplemented with 1% penicillin-streptomycin (pen-strep, Gibco). To induce Hh pathway

activity with an agonist, explants were treated with 10 μM purmorphamine[28] (APExBio) or dimethyl

sulfoxide (DMSO) vehicle for 24 hours, with a subset concurrently transfected with 100 nM

novel_miRNA_2 mimic.

Bioinformatics

Novel_miRNA_2 target genes were predicted by complementary alignment of its seed-sequence

(nucleotide position 2-8) to the 3' UTRs of all human transcripts annotated in Ensembl BioMart

(GRCh38). Putative 8mer, 7mer-m8, and 7mer-A1 matches were retained for further analysis as

these binding site configurations are recognized as the strongest and most efficient for microRNA-

mediated gene repression[49]. Genes were further assessed for microRNA accessibility by

computing the minimum free energy of the 70-nucleotide regions upstream and downstream of

the seed-sequence binding sites using RNAfold (ViennaRNA package, v.2.5.1)[50]. The mean

flanking region delta Gibbs free energy (ΔG) was compared to the average ΔG of all other 70-

nucleotide windows within the same 3' UTR; binding sites with mean flanking region ΔG above

the global 3' UTR average were prioritized[19]. To select target genes most relevant to OA

subchondral bone, genes were cross-referenced with the OsteoDIP database

(https://ophid.utoronto.ca/OsteoDIP)[20], filtering for studies conducted in "subchondral bone",

"femoral condyles", "medial and lateral tibial plateaus", and "proximal femur". Pathway core

analysis was performed using Ingenuity Pathway Analysis software (QIAGEN)[21]. Putative

transcription factor binding sites within the promoter region of *ZNF773* (transcript

NM_001304334.2) were identified using the JASPAR (https://jaspar.elixir.no/)[51] transcription

factor motif database.

AGO2-RNA immunoprecipitation

AGO2-RNA immunoprecipitation experiments were adapted from an established protocol[52].

Briefly, 100 mg primary human knee OA subchondral bone was lysed in NP40 buffer with protease

and RNase inhibitors. After pre-clearing, 200 µL lysate was incubated with 3 µg of anti-AGO2 or

IgG antibodies bound to pre-blocked Dynabeads™ Protein G (Thermofisher Scientific). IgG was

used as a control for the detection of non-specific protein binding. AGO2/IgG complexes were

washed and RNA was extracted using our published protocols[47]. RT-qPCR analysis was

performed to measure novel_miRNA_2 and U6 small nuclear RNA levels in AGO2- and IgG-

bound fractions. U6 small nuclear RNA was used as a non-microRNA control that does not

associate with RISCs and therefore should not co-precipitate with AGO2[52].

Cell mineralization assay

Cell mineralization assay

Murine MC3T3-E1 pre-osteoblasts were seeded in 12-well plates at 6.0×10^4 cells/mL and

cultured at 37°C (with 5% CO_2) in Minimum Essential Medium Alpha (α-MEM) supplemented with

10% fetal bovine serum and 1% pen-strep. At 80% confluence, cells were supplemented with 10

mM β-glycerophosphate and 50 μg/mL ascorbic acid-2-phosphate to induce differentiation.

Simultaneously, the cells were treated with 20 nM novel_miRNA_2 mimic or negative control.

After 21 days of culture, cells were fixed in 10% neutral buffered formalin (NBF) and mineralization

was assessed by von Kossa[53] and Alizarin Red S (ARS) staining[54] using established protocols.

Briefly, for von Kossa, fixed cells were stained with 1% aqueous silver nitrate under ultraviolet

light, and unreacted silver was neutralized with 5% sodium thiosulfate. For ARS, fixed cells were

stained with 2% ARS (Sigma-Aldrich), then washed thoroughly. Images were captured at 2x

magnification using an Eclipse Ti microscope (Nikon). Bound ARS dye was extracted using 10%

acetic acid and average absorbance across technical replicates measured at 405 nm using a

plate reader (Perkin-Elmer).

Animal experiments

Animal experiments

Male C57BL/6J mice at 11 weeks of age were purchased from Jackson Laboratories and

acclimatized for one week prior to surgery. All animals were housed under a 12-hour light/dark

cycle at 21°C and 30% humidity. Animals were handled by trained personnel and closely

monitored for signs of distress for the duration of the experiments to minimize suffering. Knee OA

was induced at 12 week of age using the partial medial meniscectomy (PMX) model as previously

described[8], with a concurrent group of mice undergoing sham surgery. Animals were randomized

into treatment groups comprising tail vein injections of 5 μg (in 50 μL 1X PBS) novel_miRNA_2

mimic or negative control delivered weekly according to the regimens shown in **Figure 4A**. At

endpoint (8 weeks post-surgery), animals were euthanized via CO_2 asphyxiation with cervical

dislocation secondary assurance of death, and hind limbs were harvested. Animal experiments

were approved by the HFH Institutional Animal Care and Use Committee (IACUC #1616).

Histological analyses

Mouse knee joints were fixed in 10% NBF at room temperature for 4 days followed by

decalcification using a 20% ethylenediaminetetraacetic acid (EDTA) solution for 21 days.

Samples were paraffin-embedded, coronally sectioned at 5-micron thickness onto charged slides,

then deparaffinized and stained with 0.1% Safranin-O. Cartilage damage was assessed using

OARSI scoring[55]. Joints were divided into medial and lateral tibial/femoral quadrants and graded

from 0 (no cartilage damage) to 6 (>75% cartilage thickness loss) by two independent blinded

observers, with the mean maximal quadrant score assigned to each sample. Synovitis was

assessed using the Krenn scoring system[56]. Values from 0 (normal) to 3 (severe) were assigned

for each of synovial lining thickness, stromal cell density, and inflammatory infiltration, then

summed for a maximum score of 9. For osteophytes, cross-sectional areas were manually drawn

and areas for the medial tibia and medial femur were quantified and averaged[57].

To assess novel_miRNA_2 mimic localization via *in situ* hybridization, mouse knee joints were

fixed and decalcified as described above. Tissues were then sectioned onto charged RNAse-free

slides at 2-micron thickness. Signal was visualized using a custom-designed novel_miRNA_2

miRNAScope probe (Advanced Cell Diagnostics) with the RNAScope 2.5 HD Kit, according to the

manufacturer's instructions.

Statistical analyses

All data analyses were performed using R 4.2.0 statistical software; specific R packages are

available upon request. Unless otherwise noted, all datapoints represent biological replicates. For

all experiments, normality was assessed using the Shapiro-Wilk test. For comparisons across

three or more groups, statistical significance was determined by one-way analysis of variance

(ANOVA) followed by Tukey's HSD post hoc test or the Kruskal-Wallis test followed by Dunn's

post hoc test. For comparisons between two groups, statistical significance was determined by

two-sided unpaired Welch's T-test, paired Student's T-test, or Mann-Whitney U-test. Pearson

correlation was performed between novel_miRNA_2 levels and KL grade. Multiple linear

regression analysis was used to assess associations with covariates. AUCs were generated using

the pROC v.1.18.5 R package.

References

1. Steinmetz, J.D.*, et al.* Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet Rheumatology* **5**, e508-e522 (2023).

2. Dieppe, P.A. & Lohmander, L.S. Pathogenesis and management of pain in osteoarthritis. *The Lancet* **365**, 965-973 (2005).

3. Felson, D.T. & Hodgson, R. Identifying and treating preclinical and early osteoarthritis. *Rheum Dis Clin North Am* **40**, 699-710 (2014).

4. Kaushik, A.*, et al.* Advancing osteoarthritis management: integrating new insights and addressing persistent roadblocks. *Inflammopharmacology*, 1-14 (2025).

5. Ali, S.A., Peffers, M.J., Ormseth, M.J., Jurisica, I. & Kapoor, M. The non-coding RNA interactome in joint health and disease. *Nature Reviews Rheumatology* **17**, 692-705 (2021).

6. Shang, R., Lee, S., Senavirathne, G. & Lai, E.C. microRNAs in action: biogenesis, function and regulation. *Nature Reviews Genetics* **24**, 816-833 (2023).

7. Szala, D.*, et al.* The Role of MicroRNAs in the Pathophysiology of Osteoarthritis. *Int J Mol Sci* **25**(2024).

8. Wilson, T.G.*, et al.* Circulating miR-126-3p is a mechanistic biomarker for knee osteoarthritis. *Nature Communications* **16**, 2021 (2025).

9. Wilson, T.G., Baghel, M. & Ali, S.A. Osteoarthritis year in review 2025: Genetics, genomics, and epigenetics. *Osteoarthritis Cartilage* (2025).

10. Griffiths-Jones, S., Grocock, R.J., van Dongen, S., Bateman, A. & Enright, A.J. miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res* **34**, D140-144 (2006).

11. Nalbant, E. & Akkaya-Ulum, Y.Z. Exploring regulatory mechanisms on miRNAs and their implications in inflammation-related diseases. *Clin Exp Med* **24**, 142 (2024).

517   12.   Friedländer, M.R.*, et al.* Evidence for the biogenesis of more than 1,000 novel human

518   microRNAs. *Genome Biol* **15**, R57 (2014).

519   13.   Potla, P., Ali, S.A. & Kapoor, M. A bioinformatics approach to microRNA-sequencing

520   analysis. *Osteoarthritis and Cartilage Open* **3**, 100131 (2021).

521   14.   Ali, S.A.*, et al.* Sequencing identifies a distinct signature of circulating microRNAs in early

522   radiographic knee osteoarthritis. *Osteoarthritis and Cartilage* **28**, 1471-1481 (2020).

523   15.   Luyten, F.P.*, et al.* Toward classification criteria for early osteoarthritis of the knee. *Semin*

524   *Arthritis Rheum* **47**, 457-463 (2018).

525   16.   Nevitt, M., Felson, D. & Lester, G. The osteoarthritis initiative. *Protocol for the cohort study*

526   **1**(2006).

527   17.   Fromm, B.*, et al.* A Uniform System for the Annotation of Vertebrate microRNA Genes

528   and the Evolution of the Human microRNAome. *Annu Rev Genet* **49**, 213-242 (2015).

529   18.   Riolo, G., Cantara, S., Marzocchi, C. & Ricci, C. miRNA targets: from prediction tools to

530   experimental validation. *Methods and protocols* **4**, 1 (2020).

531   19.   Kuhn, D.E.*, et al.* Experimental validation of miRNA targets. *Methods* **44**, 47-54 (2008).

532   20.   Pastrello, C.*, et al.* Osteoarthritis Data Integration Portal (OsteoDIP): a web-based gene

533   and non-coding RNA expression database. *Osteoarthritis and Cartilage Open* **4**, 100237

534   (2022).

535   21.   Krämer, A., Green, J., Pollard Jr, J. & Tugendreich, S. Causal analysis approaches in

536   ingenuity pathway analysis. *Bioinformatics* **30**, 523-530 (2014).

537   22.   Van Der Kraan, P.M. & Van Den Berg, W.B. Osteophytes: relevance and biology.

538   *Osteoarthritis and cartilage* **15**, 237-244 (2007).

539   23.   Knights, C.B., Gentry, C. & Bevan, S. Partial medial meniscectomy produces osteoarthritis

540   pain-related behaviour in female C57BL/6 mice. *Pain* **153**, 281-292 (2012).

24.   Vincent, T.L. Peripheral pain mechanisms in osteoarthritis. *Pain* **161**, S138-S146 (2020).

25. Lin, A.C.*, et al.* Modulating hedgehog signaling can attenuate the severity of osteoarthritis.

Nature Medicine **15**, 1421-1425 (2009).

26. Lian, J.B. & Stein, G.S. Runx2/Cbfa1: a multifunctional regulator of bone formation. *Curr*

Pharm Des **9**, 2677-2685 (2003).

27. Smith, A.E., Sigurbjörnsdóttir, E.S., Steingrimsson, E. & Sigurbjörnsdóttir, S. Hedgehog

signalling in bone and osteoarthritis: the role of Smoothened and cholesterol. *The FEBS*

journal **290**, 3059-3075 (2023).

28. Ali, S.A.*, et al.* Regulation of cholesterol homeostasis by hedgehog signaling in

osteoarthritic cartilage. *Arthritis & Rheumatology* **68**, 127-137 (2016).

29. Baghel, M.*, et al.* Circulating microRNA profiles in early-stage osteoarthritis and

rheumatoid arthritis. *Scientific Reports* **15**, 27612 (2025).

30. Gao, F.*, et al.* The human genome encodes a multitude of novel miRNAs. *Nucleic Acids*

Res **53**(2025).

31. Londin, E.*, et al.* Analysis of 13 cell types reveals evidence for the expression of numerous

novel primate- and tissue-specific microRNAs. *Proc Natl Acad Sci U S A* **112**, E1106-1115

(2015).

32. Nishida, Y.*, et al.* Serum Cartilage Oligomeric Matrix Protein Detects Early Osteoarthritis

in Patients With Anterior Cruciate Ligament Deficiency. *Arthroscopy* **38**, 873-878 (2022).

33. Singh, S., Jindal, D. & Khanna, R. Can serum MMP-3 diagnose early knee osteoarthritis?

J Orthop **38**, 42-46 (2023).

34. Füzéry, A.K., Levin, J., Chan, M.M. & Chan, D.W. Translation of proteomic biomarkers

into FDA approved cancer diagnostics: issues and challenges. *Clinical proteomics* **10**, 13

(2013).

35. Rocha, F.A.C. & Ali, S.A. Soluble biomarkers in osteoarthritis in 2022: year in review.

Osteoarthritis Cartilage **31**, 167-176 (2023).

36.   Jones, T.L.*, et al.* Osteoporosis, fracture, osteoarthritis & sarcopenia: A systematic review

568   of circulating microRNA association. *Bone* **152**, 116068 (2021).

569   37.   Bauer, D.*, et al.* Classification of osteoarthritis biomarkers: a proposed approach.

570   *Osteoarthritis and Cartilage* **14**, 723-727 (2006).

571   38.   Donell, S. Subchondral bone remodelling in osteoarthritis. *EFORT Open Rev* **4**, 221-229

572   (2019).

573   39.   Vicente, R., Noël, D., Pers, Y.M., Apparailly, F. & Jorgensen, C. Deregulation and

574   therapeutic potential of microRNAs in arthritic diseases. *Nat Rev Rheumatol* **12**, 211-220

575   (2016).

576   40.   Ziemian, S.N., Witkowski, A.M., Wright, T.M., Otero, M. & van der Meulen, M.C.H. Early

577   inhibition of subchondral bone remodeling slows load-induced posttraumatic osteoarthritis

578   development in mice. *J Bone Miner Res* **36**, 2027-2038 (2021).

579   41.   Crowe, N.*, et al.* Detecting new microRNAs in human osteoarthritic chondrocytes identifies

580   miR-3085 as a human, chondrocyte-selective, microRNA. *Osteoarthritis Cartilage* **24**,

581   534-543 (2016).

582   42.   Guo, Z.*, et al.* Genome-wide survey of tissue-specific microRNA and transcription factor

583   regulatory networks in 12 tissues. *Sci Rep* **4**, 5150 (2014).

584   43.   Lex, R.K.*, et al.* GLI transcriptional repression is inert prior to Hedgehog pathway

585   activation. *Nat Commun* **13**, 808 (2022).

586   44.   Xiao, W.F., Li, Y.S., Deng, A., Yang, Y.T. & He, M. Functional role of hedgehog pathway

587   in osteoarthritis. *Cell Biochem Funct* **38**, 122-129 (2020).

588   45.   Seyhan, A.A. Trials and Tribulations of MicroRNA Therapeutics. *Int J Mol Sci* **25**(2024).

589   46.   World Medical Association Declaration of Helsinki: ethical principles for medical research

590   involving human subjects. *Jama* **310**, 2191-2194 (2013).

591   47.   Wilson, T., Kaur, N., Davis, J. & Ali, S.A. Tissue collection and RNA extraction from the

592   human osteoarthritic knee joint. *Journal of Visualized Experiments (JoVE)*, e62718 (2021).

48.   Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time

quantitative PCR and the 2− ΔΔCT method. *methods* **25**, 402-408 (2001).

49.   Grimson, A.*, et al.* MicroRNA targeting specificity in mammals: determinants beyond seed

pairing. *Mol Cell* **27**, 91-105 (2007).

50.   Lorenz, R.*, et al.* ViennaRNA Package 2.0. *Algorithms Mol Biol* **6**, 26 (2011).

51.   Rauluseviciute, I.*, et al.* JASPAR 2024: 20th anniversary of the open-access database of

transcription factor binding profiles. *Nucleic acids research* **52**, D174-D182 (2024).

52.   Pai, B.*, et al.* NMDA receptor-dependent regulation of miRNA expression and association

with Argonaute during LTP in vivo. *Front Cell Neurosci* **7**, 285 (2014).

53.   Shima, W.N.*, et al.* Rapid growth and osteogenic differentiation of mesenchymal stem

cells isolated from human bone marrow. *Exp Ther Med* **9**, 2202-2206 (2015).

54.   Gregory, C.A., Gunn, W.G., Peister, A. & Prockop, D.J. An Alizarin red-based assay of

mineralization by adherent cells in culture: comparison with cetylpyridinium chloride

extraction. *Analytical biochemistry* **329**, 77-84 (2004).

55.   Glasson, S., Chambers, M., Van Den Berg, W. & Little, C. The OARSI histopathology

initiative–recommendations for histological assessments of osteoarthritis in the mouse.

Osteoarthritis and cartilage **18**, S17-S23 (2010).

56.   Krenn, V.*, et al.* Grading of chronic synovitis--a histopathological grading system for

molecular and diagnostic pathology. *Pathol Res Pract* **198**, 317-325 (2002).

57.   Armstrong, A.R., Carlson, C.S., Rendahl, A.K. & Loeser, R.F. Optimization of histologic

grading schemes in spontaneous and surgically-induced murine models of osteoarthritis.

Osteoarthritis and cartilage **29**, 536-546 (2021).

Acknowledgements

MB discloses support for this research from the Postdoctoral/Resident Fellowship awarded by the Orland Bethel Family Musculoskeletal Research Center, University of Pittsburgh Department of Orthopaedic Surgery, and Orthopaedic Research Society. We thank participants of the Henry Ford Health OA Cohort for donating biospecimens.

Author contributions

MB, TGW, and SAA were involved in study conception and design. MB and TGW performed experimental work and data acquisition. TB, JD, and VM contributed to the Henry Ford Health OA Cohort. MB, TGW, and SAA performed data analysis, interpretation, and drafted the manuscript. All authors contributed to manuscript revisions and approved the final version.

Competing Interests

SAA declares the following patent: Kapoor M, Ali SA, Gandhi R, & Appleton T. US Provisional Patent Application No. 63/033,463. Circulating MicroRNAs in Knee Osteoarthritis and Uses Thereof, filed on June 2, 2020. All other authors declare no conflicts of interest.

Figure Legends

Figure 1. Circulating novel_miRNA_2 distinguishes early-stage knee OA. A) Overview of the approach used by Ali et al. (2020)[14] to identify four novel microRNAs prevalent in early-stage knee OA plasma. Image created in BioRender. B) Relative plasma levels of novel_miRNA_2 in the HFH OA Cohort. Values represent the fold-change relative to non-OA controls (n = 16/group). Bars represent mean ± 95% confidence interval. *p < 0.05 as determined by one-way ANOVA with Tukey's HSD post hoc test. C) Pearson correlation of plasma novel_miRNA_2 levels versus Kellgren-Lawrence (KL) grade (n = 40). Data fitted from novel_miRNA_2 plasma levels relative to a reference microRNA (miR-24-3p). Black line = fitted linear model. Grey shaded region = 95% confidence interval. D) Area under the receiver operating characteristic curve (AUC) analysis evaluating the accuracy of novel_miRNA_2 plasma levels in distinguishing early-stage knee OA (EOA) from non-OA controls (blue line) and late-stage knee OA (LOA; red line). E) Multiple linear regression analysis evaluating the association of covariates with plasma novel_miRNA_2 levels. M = male, F = female, BMI = body mass index, 95% CI = confidence interval. Statistical significance for regression coefficients determined by two-sided t-tests. P-values: B) p = 0.000 (Early Knee OA vs. Non-OA), p = 0.002 (Early Knee OA vs. Late Knee OA), p = 0.003 (Late Knee OA vs. Non-OA).

Figure 2. Novel_miRNA_2 functions as a canonical microRNA. A) Overview of the putative biogenesis of novel_miRNA_2. RISC = RNA-induced silencing complex. Image created in BioRender. B) Predicted secondary structure of the novel_miRNA_2 precursor located in the *ZNF773* host gene on human chromosome 19 (Chr19). Mature novel_miRNA_2 (highlighted yellow) originates from the 5' arm of the precursor. Image created in BioRender. C) *ZNF773*, D) pri-novel_miRNA_2, and E) mature novel_miRNA_2 levels in early- (n = 3-7) and late-stage (n = 7) knee OA tissues. Data represent fold-change values relative to the average levels in corresponding late-stage knee OA tissues. Bars represent mean ± 95% confidence interval. *p <

0.05 as determined by two-sided Mann-Whitney U-test (*ZNF773*) or two-sided Welch's T-test (pri-

novel_miRNA_2 and novel_miRNA_2). "Bone" = subchondral bone, "FP" = infrapatellar fat pad,

"Cart" = articular cartilage, "Syn" = synovium. F) Overview of AGO2-RNA immunoprecipitation

assay in knee OA subchondral bone. Image created in BioRender. G) Relative enrichment of

novel_miRNA_2 and U6 small nuclear RNA negative control (snRNA) in IgG- or AGO2-bound

fractions as measured by RT-qPCR. Data represent fold-change values relative to the

corresponding IgG-bound fraction (n = 3). Bars represent mean ± 95% confidence. *p < 0.05 as

determined by two-sided Welch's T-test. P-values: C) p = 0.007 (Bone), p = 0.001 (FP), p = 0.067

(Cart), p = 0.035 (Syn). D) p = 0.000 (Bone), p = 0.005 (FP), p = 0.055 (Cart), p = 0.109 (Syn). E)

p = 0.018 (Bone), p = 0.018 (FP), p = 0.017 (Cart), p = 0.042 (Syn). G) p = 0.021

(novel_miRNA_2), p = 0.347 (U6 snRNA).

Figure 3. Novel_miRNA_2 inhibits target genes in knee OA subchondral bone. A) Strategy

to prioritize predicted novel_miRNA_2 target genes in OA. ΔG = Gibbs free energy. B) List of the

13 shortlisted target genes with features of their predicted novel_miRNA_2 binding sites, ranked

by predicted flanking region ΔG. C) RT-qPCR in knee OA subchondral bone transfected with

novel_miRNA_2 mimic or negative control (n = 5). Data represented relative to negative control-

treated tissues (dashed line). Bars represent mean ± 95% confidence interval. *p < 0.05 versus

matched negative control. D) Spectrophotometric quantification of Alizarin Red S staining (n = 6

technical replicates). Data represented relative to negative control-treated cells. Bars represent

mean ± 95% confidence interval. *p < 0.05. E) Representative images of MC3T3-E1 cells stained

with von Kossa or Alizarin Red S dyes to visualize mineralization following transfection with

novel_miRNA_2 mimic or negative control. Scale bars = 1 mm. All significance assessed by

paired two-sided Student's T-test. P-values: C) p = 0.000 (novel_miRNA_2), p = 0.007 (*ASPN*),

p = 0.031 (*RUNX2*), p = 0.040 (*ATRNL1*), p = 0.041 (*ADRA2A*), p = 0.031 (*SLC2A4*), p = 0.047

(*ITGA11*), p = 0.019 (*IL11*), p = 0.023 (*ALPL*), p = 0.041 (*MMP25*). D) p = 0.000.

Figure 4. Novel_miRNA_2 has a protective effect in early-stage knee OA. A) Overview of the experimental design for mouse surgeries and novel_miRNA_2 mimic treatments. PMX = partial medial meniscectomy. Sx = surgery. Tx = treatment. Image created in BioRender. B) Representative images from *in situ* hybridization depicting localization of novel_miRNA_2 mimic in mouse knee subchondral bone. Scale bars = 200 μm. Insets show magnified regions (scale bars = 50 μm, arrows = positive signal). C) Representative coronal sections of mouse operated knee, stained with Safranin-O. Scale bars = 1 mm. Insets show magnified regions (scale bars = 100 μm, arrows = examples of cartilage damage). D) OARSI scoring of PMX and sham mice following novel_miRNA_2 mimic or control treatments (n = 5). Bars represent mean maximal quadrant score ± 95% confidence interval. *$p < 0.05$. E) Representative coronal sections of mouse operated knee demonstrating osteophyte burden. Scale bars = 250 μm. Brackets = approximate osteophyte diameter. F) Osteophyte area in PMX and sham mice following novel_miRNA_2 mimic or control treatments (n = 5). Datapoints represent the mean of the medial tibial and medial femoral osteophyte area for each mouse. Bars represent the mean osteophyte area ± 95% confidence interval, *$p < 0.05$. All significance assessed by two-sided Mann-Whitney U-test with Benjamini-Hochberg multiple testing correction. P-values: D) $p = 0.030$ [novel_miRNA_2 mimic: PMX (Early Tx) vs. PMX (Late Tx)], $p = 0.016$ [PMX (Early Tx): Negative control vs. novel_miRNA_2 mimic]. F) $p = 0.024$ [novel_miRNA_2 mimic: PMX (Early Tx) vs. PMX (Late Tx)], $p = 0.032$ [PMX (Early Tx): Negative control vs. novel_miRNA_2 mimic].

Figure 5. Hedgehog (Hh) signaling may regulate novel_miRNA_2 levels in knee OA. A) GLI consensus binding motifs in the region 2.5 kb upstream of novel_miRNA_2 within *ZNF773*. Red = positive strand, blue = negative strand. TSS = transcription start site. B) RT-qPCR in human knee OA subchondral bone (n = 7/group). Data represent fold-change relative to late-stage knee OA tissues. Bars represent mean ± 95% confidence interval. *$p < 0.05$ as determined by two-

sided Welch's T-test. C) Experimental design for Hh agonist (purmorphamine) treatments. Vehicle = dimethyl sulfoxide (DMSO). Image created in BioRender. D) RT-qPCR in late-stage knee OA subchondral bone explants following Hh agonist treatment (n = 5/group). Data represent fold-change relative to paired vehicle (DMSO) control. Bars represent mean ± 95% confidence interval. *p < 0.05. E) RT-qPCR in late-stage knee OA subchondral bone explants (n = 5/group) following treatment with Hh agonist and concurrent novel_miRNA_2 mimic ("mimic"). Data represent fold-change relative to Hh agonist alone. Bars represent mean ± 95% confidence interval. *p < 0.05 as determined by two-sided paired Student's T-test. P-values: B) p = 0.000 (*GLI1*), p = 0.000 (*PTCH1*), p = 0.003 (*HHIP*), p = 0.001 (*RUNX2*). D) p = 0.030 (*GLI1*), p = 0.022 (*PTCH1*), p = 0.008 (*HHIP*), p = 0.013 (*ZNF773*), p = 0.015 (pri-novel_miRNA_2), p = 0.005 (novel_miRNA_2), p = 0.019 (*RUNX2*). E) p = 0.000 (novel_miRNA_2), p = 0.001 (*RUNX2*).

Figure 6. Novel_miRNA_2 may mediate the effects of Hedgehog (Hh) signaling on *RUNX2* in knee OA subchondral bone. In early-stage knee OA subchondral bone (left), reduced Hh pathway activity coincides with elevated novel_miRNA_2 biogenesis and expression levels, which can repress target genes such as *RUNX2*. In late-stage knee OA subchondral bone (right), increased Hh pathway activity may suppress novel_miRNA_2 levels, potentially via GLI repressor isoforms, and allow *RUNX2* to be elevated. When novel_miRNA_2 mimic is delivered beginning in early stages of OA, its protective effects are maintained (bottom). Image created in BioRender.

<u>**Supplemental Figures**</u>

Supplemental Figure 1. Novel microRNA levels in OA plasma. RT-qPCR for (A)

novel_miRNA_1, (B) novel_miRNA_3, and (C) novel_miRNA_4 in the HFH OA Cohort. Data

represent the fold-change relative to non-OA controls. Bars represent mean ± 95% confidence

interval. Novel_miRNA_3 was not in the detectable range of RT-qPCR for 38/48 of the samples.

Significance not detected for any microRNA as assessed by Kruskal-Wallis test, p = 0.232

(novel_miRNA_1), p = N/A (novel_miRNA_3), p = 0.434 (novel_miRNA_4).

Supplemental Figure 2. Accuracy of novel_miRNA_2 plasma levels in distinguishing late-

stage knee OA (LOA) from non-OA controls. Area under the receiver operating characteristic

curve (AUC) analysis.

A

Mechanism name	Genes	IPA designation
Osteoarthritis	*ADRA2A, APOD, ASPN, ATRNL1, IL11, LEP, MMP25, PARD6G, RUNX2, SLC2A4*	Diseases and Functions
Hip or knee osteoarthritis	*ADRA2A, ASPN, IL11, RUNX2, SLC2A4*	Diseases and Functions
Osteoarthritis Pathway	*ADIPOQ, ALPL, ITGA11, LEP, RUNX2*	Canonical Pathway

B

Supplemental Figure 3. Predicted novel_miRNA_2 target genes in curated 'Diseases and Functions' or 'Canonical Pathways' related to OA. A) Table of novel_miRNA_2 target genes stratified by Ingenuity Pathway Analysis (IPA) software core analysis results. B) 'Osteoarthritis Signaling Pathways' schematic generated by IPA showing predicted novel_miRNA_2 targets as shaded symbols.

Supplemental Figure 4. Male mice with knee OA show no change in synovitis following novel_miRNA_2 mimic treatment. A) Representative medial synovium from coronal sections of mouse operated knees. Scale bars = 250μm. PMX = partial medial meniscectomy. Tx = treatment. B) Krenn synovitis scoring in PMX and sham mice following novel_miRNA_2 mimic or negative control treatments (n = 5). Bars represent mean synovitis score ± 95% confidence interval. NS = not significant as determined by two-sided Mann-Whitney U-test. P-values: p = 0.141 [PMX (Early Tx): Negative control vs. novel_miRNA_2 mimic], p = 0.833 [novel_miRNA_2 mimic: PMX (Early Tx) vs. PMX (Late Tx)].

	Non OA	Early Knee OA	Late Knee OA	p-value
n (48 total)	16	16	16	-
Age (years) Mean (SD)	58.6 (11.2)	46.6 (12.2)	64.1 (8.3)	<0.01
Sex (female) n (%)	8 (50.0)	7 (43.8)	8 (50.0)	0.92
BMI (kg/m^2) Mean (SD)	27.0 (3.2)	27.6 (5.1)	31.9 (5.2)	<0.01
Race (white) n (%)	15 (93.8)	10 (62.5)	13 (81.2)	0.24

814 **Supplemental Table 1. Clinicodemographic variables of plasma samples used from the**

815 **HFH OA Cohort.** n = sample size, SD = standard deviation, BMI = body mass index. Significance

816 between groups assessed by one-way ANOVA for continuous variables and two-sided Chi-square

817 test for categorical variables. P-values: p = 0.0001 (Age), p = 0.007 (BMI).

MicroRNA/gene symbol	Assay ID (TaqMan) or 5'–3' sequences (SYBR)
novel_miRNA_1	CSFXEVR
novel_miRNA_2	CTDJYDE
novel_miRNA_3	CTFVMKE
novel_miRNA_4	CTGZF6C
pri-novel_miRNA_2	APRWRTD
ZNF773	Hs00828818_m1
GAPDH (TaqMan)	Hs99999905_m1
ADRA2A	5'-CTTCTGGTTCGGCTACTGCAAC-3' - Forward 5'-GGAAACCTCACACGATCCGCTT-3' - Reverse
ADIPOQ	5'-CAGGCCGTGATGGCAGAGATG-3' - Forward 5'-GGTTTCACCGATGTCTCCCTTAG-3' - Reverse
ALPL	5'-GCTGTAAGGACATCGCCTACCA-3' - Forward 5'-CCTGGCTTTCTCGTCACTCTCA-3' - Reverse
APOD	5'-CAACTACTCACTAATGGAAAACGG-3' - Forward 5'-CTTGGCAGGCTCTGTGAGGTTA-3' - Reverse
ASPN	5'-CCACCAACTTTATTGGAGCTTCAC-3' - Forward 5'-CGTGGTATGTTAGCAAGACTCCC-3' - Reverse
ATRNL1	5'-AGATGATCGCCACCATACTGCC-3' - Forward 5'-CTGTTGAACCGACAGACCACGT-3' - Reverse
GLI1	5'-AGCCTTCAGCAATGCCAGTGAC-3' - Forward 5'-GTCAGGACCATGCACTGTCTTG-3' - Reverse
HHIP	5'-GCCATTCAGTAATGGTCCTTTGG-3' - Forward 5'-TGCCACTGCTTTGTCACAGGAC-3' - Reverse
IL11	5'-GGACCACAACCTGGATTCCCTG-3' - Forward 5'-AGTAGGTCCGCTCGCAGCCTT-3' - Reverse
ITGA11	5'-GCCTCCAGTATTTTGGCTGCAG-3' - Forward 5'-GCTCAAAGTGGAGGCTGGCATT-3' - Reverse
LEP	5'-GCTGTGCCCATCCAAAAAGTCC-3' - Forward 5'-CCCAGGAATGAAGTCCAAACCG-3' - Reverse
MMP25	5'-TGACAAGCCCACAAGGAAACCC-3' - Forward 5'-GATGGCGTCAAAATTGCCCTCAC-3' - Reverse
PARD6G	5'-GAGACCTGCTGCCCATCAACAA-3' - Forward 5'-CGCCGAGGCTGCCACGCTC-3' - Reverse
PTCH1	5'-GCTGCACTACTTCAGAGACTGG-3' - Forward 5'-CACCAGGAGTTTGTAGGCAAGG-3' - Reverse
RUNX2	5'-CCCAGTATGAGAGTAGGTGTCC-3' - Forward 5'-GGGTAAGACTGGTCATAGGACC-3' - Reverse
SLC2A4	5'-CCATCCTGATGACTGTGGCTCT-3' - Forward 5'-GCCACGATGAACCAAGGAATGG-3' - Reverse
GAPDH (SYBR)	5'-CATCACTGCCACCCAGAAGACTG-3' - Forward 5'-ATGCCAGTGAGCTTCCCGTTCAG-3' - Reverse

830   **Supplemental Table 2. List of probes and primers used for RT-qPCR experiments.**

Figures

Figure 1.

Figure 2.

B

Gene symbol	Gene name	Molecule type	Binding site type (#)	Flanking ΔG (kcal/mol)	Non-flanking ΔG (kcal/mol)
APOD	Apolipoprotein D	Lipoprotein	7mer (1)	-0.7	-14.4
ASPN	Asporin	Proteoglycan	8mer (1)	-4.0	-8.5
RUNX2	Runt Related Transcription Factor 2	Transcription factor	7mer (1)	-7.2	-10.5
ATRNL1	Attractin-Like 1	Glycoprotein	8mer (1), 6mer (2)	-7.5	-10.8
PARD6G	Partitioning Defective 6 Homolog Gamma	Adapter protein	7mer (1)	-10.0	-13.0
ADRA2A	Adrenoceptor Alpha 2A	Adrenoceptor	7mer (1)	-10.2	-14.6
ADIPOQ	Adiponectin	Adipokine	7mer (2), 6mer (1)	-10.8	-11.2
SLC2A4	Solute Carrier Family 2 Member 4	Transporter	7mer (1)	-11.7	-16.4
ITGA11	Integrin Subunit Alpha 11	Alpha integrin	7mer (1), 6mer (2)	-11.9	-12.1
IL11	Interleukin 11	Cytokine	8mer (1), 6mer (1)	-13.1	-16.2
ALPL	Alkaline Phosphatase, Biomineralization Associated	Enzyme	7mer (1)	-13.3	-15.5
LEP	Leptin	Adipokine	7mer (1)	-14.4	-16.9
MMP25	Matrix Metallopeptidase 25	Enzyme	7mer (1)	-16.0	-21.6

863 **Figure 3.**

879 **Figure 4.**

890   **Figure 5.**

898 **Figure 6.**